

PRODUCT MONOGRAPH

Pr MYLAN-LISINOPRIL

(Lisinopril Tablets, USP)

Tablets 5 mg, 10 mg and 20 mg

(Lisinopril as lisinopril dihydrate)

Angiotensin Converting Enzyme Inhibitor

Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6

Date of Revision:
December 19, 2016

Submission Control number: 192608

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS	4
ADVERSE REACTIONS.....	11
DRUG INTERACTIONS	17
DOSAGE AND ADMINISTRATION	19
OVERDOSAGE	22
ACTION AND CLINICAL PHARMACOLOGY	23
STORAGE AND STABILITY	26
DOSAGE FORMS, COMPOSITION AND PACKAGING	26
PART II: SCIENTIFIC INFORMATION	27
PHARMACEUTICAL INFORMATION.....	27
CLINICAL TRIALS	28
DETAILED PHARMACOLOGY	29
MICROBIOLOGY	30
TOXICOLOGY	31
REFERENCES	40
PART III: CONSUMER INFORMATION.....	42

Pr MYLAN-LISINOPRIL

(Lisinopril Tablets, USP)
5 mg, 10 mg and 20 mg

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	All Nonmedicinal Ingredients
Oral	Tablet 5 mg, 10 mg and 20 mg	Corn starch, dibasic calcium phosphate, magnesium stearate, mannitol 60, talc and red iron oxide #30

INDICATIONS AND CLINICAL USE

Hypertension

MYLAN-LISINOPRIL (lisinopril) is indicated in the treatment of essential hypertension and in renovascular hypertension. It may be used alone or concomitantly with thiazide diuretics. A great majority of patients (>80%) with severe hypertension required combination therapy.

Heart Failure

MYLAN-LISINOPRIL is indicated in the management of symptomatic congestive heart failure as adjunctive treatment with diuretics, and where appropriate, digitalis. Treatment with MYLAN-LISINOPRIL should be initiated under close medical supervision, usually in a hospital.

High doses of MYLAN-LISINOPRIL reduce the risk of the combined outcomes of mortality and hospitalization (see ACTION AND CLINICAL PHARMACOLOGY, and DOSAGE AND ADMINISTRATION).

Treatment Following Acute Myocardial Infarction

MYLAN-LISINOPRIL is indicated in the treatment of hemodynamically stable patients as early as within 24 hours following acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, ASA and beta-blocker(s).

Therapy with MYLAN-LISINOPRIL should be reassessed after 6 weeks. If there is no evidence of symptomatic or asymptomatic left ventricular dysfunction, treatment with MYLAN-LISINOPRIL can be stopped.

MYLAN-LISINOPRIL should not be used if systolic blood pressure is <100 mm Hg, if clinically relevant renal failure is present, or if there is a history of bilateral stenosis of the renal

arteries (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension Following Acute Myocardial Infarction; and WARNINGS AND PRECAUTIONS, Renal, Renal Impairment).

CONTRAINDICATIONS

MYLAN-LISINOPRIL (lisinopril) is contraindicated in patients who:

- Are hypersensitive to any component of this product;
- Have a known allergy to angiotensin converting enzyme (ACE) inhibitors;
- Have a history of angioedema relating to previous treatment with an ACE inhibitor;
- Have hereditary or idiopathic angioedema;
- Are taking aliskiren-containing drugs and have diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment ($GFR < 60 \text{ ml/min/1.73m}^2$) (see WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System (RAS), PRECAUTIONS, Renal Impairment, and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs).

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

When used in pregnancy, ACE inhibitors can cause injury or even death of the developing fetus. When pregnancy is detected, MYLAN-LISINOPRIL should be discontinued as soon as possible (see WARNINGS AND PRECAUTIONS, Use in Pregnancy).

Carcinogenesis and Mutagenesis

See TOXICOLOGY for discussion on animal data.

Cardiovascular

Hypotension

Symptomatic hypotension has occurred after administration of lisinopril, usually after the first or second dose or when the dose was increased. It is more likely to occur in patients who are volume depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea, vomiting, or possibly in patients with renin-dependant renovascular hypertension (see DOSAGE AND ADMINISTRATION). In patients with severe CHF, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death. Because blood pressure could potentially fall, patients at risk for hypotension should start therapy under very close medical supervision, usually in a hospital. Such patients should be followed closely for the

first 2 weeks of treatment and whenever the dose of lisinopril and/or diuretic is increased. Similar considerations apply to patients with ischemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident (see ADVERSE REACTIONS).

If hypotension occurs, the patient should be placed in supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response may not be a contraindication to further doses. These can usually be given to hypertensive patients without difficulty once the blood pressure has increased after volume expansion. However, lower MYLAN-LISINOPRIL doses and/or reduced concomitant diuretic therapy should be considered.

If hypotension occurs during treatment following acute myocardial infarction, consideration should be given to MYLAN-LISINOPRIL discontinuation (see ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, Treatment Following Acute Myocardial Infarction).

In some patients with congestive heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with MYLAN-LISINOPRIL. If hypotension occurs, a reduction of dose or discontinuation of therapy should be considered.

Hypotension Following Acute Myocardial Infarction

Lisinopril treatment following acute myocardial infarction must not be initiated in patients at risk of further serious hemodynamic deterioration after vasodilator treatment.

These include patients with systolic blood pressure of ≤ 100 mm Hg or those in cardiogenic shock.

During the first 3 days following the infarction, dosage reduction should occur if systolic blood pressure is between 100 and 120 mm Hg (see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, Treatment Following Acute Myocardial Infarction).

Patients with myocardial infarction in the GISSI-3 study treated with MYLAN-LISINOPRIL, had a higher (9.0% vs 3.7%) incidence of persistent hypotension (systolic blood pressure < 90 mm Hg for more than 1 hour) than placebo.

Valvular Stenosis, Hypertrophic Cardiomyopathy

There is concern on theoretical grounds that patients with aortic stenosis or hypertrophic cardiomyopathy might be at particular risk of decreased coronary perfusion when treated with vasodilators.

MYLAN-LISINOPRIL should be given with caution to these patients.

Endocrine and Metabolism

Diabetic Patients

In diabetic patients treated with oral antidiabetics or insulin, glycemic control should be closely monitored during the first month of treatment with lisinopril (See DRUG INTERACTIONS).

Hematologic

Neutropenia/Agranulocytosis

Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. Several cases of agranulocytosis and neutropenia have been reported in which a causal relationship to lisinopril cannot be excluded. Current experience with the drug shows the incidence to be rare. Periodic monitoring of white blood cell counts should be considered, especially in patients with collagen vascular disease and renal disease.

Hyperkalemia

In clinical trials with daily doses of 2.5 to 20 mg, hyperkalemia (serum potassium >5.7 mEq/L) occurred in approximately 2.2% of hypertensive patients and 4.0% of patients with CHF. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in approximately 0.1% of hypertensive patients.

As shown in the ATLAS trial (see ACTION AND CLINICAL PHARMACOLOGY), high dose (≤ 35 mg) versus low dose (≤ 5 mg) treatment may predispose CHF patients to hyperkalemia (6.4% versus 3.5%). This event was manageable and rarely led to treatment withdrawal. Therapy discontinuation rates due to hyperkalemia for high versus low dose were 0.4% versus 0.1%, respectively. Risk factors for the development of hyperkalemia may include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene or amiloride), potassium supplements, other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole) and/or potassium-containing salt substitutes. (See WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS).

Hepatic/Biliary/Pancreatic

Patients with Impaired Liver Function

Hepatitis – either hepatocellular or cholestatic, jaundice, marked elevations of liver enzymes and/or serum bilirubin have occurred during therapy with lisinopril in patients with or without pre-existing liver abnormalities (see ADVERSE REACTIONS). Very rarely, it has been reported that in some patients the undesirable development of hepatitis has progressed to hepatic failure. Patients receiving MYLAN-LISINOPRIL who develop jaundice or marketed elevation of hepatic enzymes should discontinue MYLAN-LISINOPRIL and receive appropriate medical follow-up (See WARNINGS AND PRECAUTIONS – Patients with Impaired Liver Function). Should the patient receiving MYLAN-LISINOPRIL experience any unexplained symptoms (see WARNINGS AND PRECAUTIONS, General, Information for Patients), particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and

any other necessary investigation be carried out. Discontinuation of MYLAN-LISINOPRIL should be considered when appropriate.

There are no adequate studies in patients with cirrhosis and/or liver dysfunction. MYLAN-LISINOPRIL should be used with particular caution in patients with pre-existing liver abnormalities. In such patients baseline liver function tests should be obtained before administration of the drug and close monitoring of response and metabolic effects should apply.

Immune

Angioedema

Angioedema has been uncommonly reported in patients treated with lisinopril and may occur at any time during therapy. Angioedema associated with laryngeal or tongue edema and/or shock may be fatal. If angioedema occurs, MYLAN-LISINOPRIL should be promptly discontinued and the patient should be treated, and observed until the swelling subsides. Where swelling is confined only to the tongue, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. However, where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, and especially in cases where there has been a history of airway surgery, emergency therapy should be administered promptly when indicated. This includes giving subcutaneous adrenaline (0.5 mL 1:1000), and/or maintaining a patent airway. The patient should be under close medical supervision until complete and sustained symptom resolution has occurred.

The incidence of angioedema during ACE inhibitor therapy has been reported to be higher in black than in non-black patients.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see CONTRAINDICATIONS).

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. Caution should be used when these drugs are used concomitantly (see DRUG INTERACTIONS).

Dual blockade of the Renin-Angiotensin System (RAS)

There is evidence that co-administration of angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, or of angiotensin receptor antagonists (ARBs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR <60 ml/min/1.73m²). Therefore, the use of lisinopril in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS).

Further, co-administration of ACE inhibitors, including lisinopril, with other agents blocking the RAS, such as ARBs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, decreased renal failure (including acute renal failure), and hyperkalemia.

Avoid the concomitant use of ACE inhibitors and ARBs in patients with diabetic nephropathy.

If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

Anaphylactoid Reactions During Membrane Exposure

Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes [e.g.: polyacrylonitrile (PAN) and during low-density lipoproteins (LDL) apheresis with dextran sulphate] and treated concomitantly with an ACE inhibitor. Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur. Symptoms are not relieved by antihistamines. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.

Anaphylactoid Reactions During Desensitization

There have been isolated reports of patients experiencing sustained life threatening anaphylactoid reactions while receiving ACE inhibitors during desensitizing treatment with hymenoptera (bees, wasps) venom. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for at least 24 hours, but they have reappeared upon inadvertent rechallenge.

Nitritoid Reactions – Gold

Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy (see PRECAUTIONS, Drug Interactions).

Occupation Hazards

Ability to drive and use machines: dizziness or tiredness may occur during treatment with lisinopril.

Peri-Operative Considerations

Surgery/Anesthesia

In patients undergoing major surgery or during anesthesia with agents that produce hypotension, lisinopril blocks angiotensin II formation, secondary to compensatory renin release. If

hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Renal

Renal Impairment

As a consequence of inhibiting the RAAS, changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS, such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe CHF, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk.

The use of ACE inhibitors, including lisinopril, or ARBs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR <60ml/min/1.73m²) (see CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACE inhibitors, or aliskiren-containing drugs).

In acute myocardial infarction, treatment with lisinopril should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/L and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during treatment with MYLAN-LISINOPRIL (serum creatinine concentration exceeding 265 micromol/L or a doubling from the pre-treatment value), then the physician should consider withdrawal of MYLAN-LISINOPRIL.

Use of MYLAN-LISINOPRIL (lisinopril) should include appropriate assessment of renal function.

Respiratory

Cough

A dry, persistent cough, which usually disappears only after withdrawal or lowering of the dose of MYLAN-LISINOPRIL, has been reported.

Such a possibility should be considered as part of the differential diagnosis of the cough.

Special Populations

Pregnant Women:

ACE inhibitors must be avoided during pregnancy because these agents can cause fetal and neonatal morbidity and mortality when administered to pregnant women. When pregnancy is detected, MYLAN-LISINOPRIL should be discontinued as soon as possible.

The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function, associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development.

Prematurity, and patent ductus arteriosus and other structural cardiac malformations, as well as neurologic malformations, have also been reported following exposure in the first trimester of pregnancy.

Infants with a history of *in utero* exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed towards support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit.

Lisinopril has been removed from the neonatal circulation by peritoneal dialysis.

Animal Data

Lisinopril was not teratogenic in mice treated on days 6-15 of gestation with ≤ 1000 mg/kg/day (625 times the maximum recommended human dose). There was an increase in fetal resorptions at doses ≥ 100 mg/kg; at doses of 1000 mg/kg, this was prevented by saline supplementation. There was no fetotoxicity or teratogenicity in rats treated with ≤ 300 mg/kg/day (188x the maximum recommended dose) of lisinopril at days 6-17 of gestation. In rats receiving lisinopril from day 15 of gestation through day 21 postpartum, there was an increased incidence in pup deaths on days 2-7 postpartum and a lower average body weight of pups on day 21 postpartum. The increase in pup deaths and decrease in pup weight did not occur with maternal saline supplementation.

Lisinopril, at doses ≤ 1 mg/kg/day, was not teratogenic when given throughout the organogenic period in saline supplemented rabbits. Saline supplementation (physiologic saline in place of tap water) was used to eliminate maternotoxic effects and enable evaluation of the teratogenic potential at the highest possible dosage level.

Fetotoxicity was demonstrated in rabbits by an increased incidence of fetal resorptions at an oral dose of lisinopril of 1 mg/kg/day and by an increased incidence of incomplete ossification at the lowest dose tested (0.1 mg/kg/day). A single intravenous dose of 15 mg/kg of lisinopril administered to pregnant rabbits on gestation days 16, 21 or 26 resulted in 88-100% fetal death.

By whole body autoradiography, radioactivity was found in the placenta following administration of labeled lisinopril to pregnant rats, but none was found in the fetuses.

Use in Nursing Women:

The presence of concentrations of ACE inhibitor have been reported in human milk. Use of ACE inhibitors is not recommended during breast feeding.

Race:

ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.

The antihypertensive effect of ACEinhibitors is generally lower in black patients (usually a low-renin hypertensive population) than in non-black patients.

Pediatrics (6-16 years old< 18 years of age):

Antihypertensive effects of lisinopril have been established in hypertensive pediatric patients aged 6 to 16 years. There are no data of the effects of lisinopril in hypertensive patients under the age of <6 or in patients with glomerular filtration rate GFR <30 mL/min/1.73 m² (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics, Pharmacokinetics, DOSAGE AND ADMINISTRATION, Pediatric Patients).

Monitoring and Laboratory Tests

No data is available.

ADVERSE REACTIONS**Clinical Trial Adverse Drug Reactions**

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In controlled clinical trials involving 3269 patients, 2633 patients with hypertension and 636 patients with CHF, excluding the ATLAS CHF study patients (see ACTION and CLINICAL PHARMACOLOGY), the most frequent clinical adverse reactions were: dizziness (4.4%), headache (5.6%), asthenia/fatigue (2.7%), diarrhea (1.8%) and cough (3.0%), all of which were more frequent than in placebo-treated patients. Discontinuation of therapy was required in 5.9% of patients.

For adverse reactions which occurred in hypertensive patients and patients with CHF treated with lisinopril in controlled clinical trials, comparative incidence data are listed in the table below.

Adverse Events in Controlled Clinical Trials

Incidence of adverse reactions occurring in patients treated with lisinopril in controlled clinical trials.

		Hypertension n=2 633 (%)	Congestive Heart Failure n=636 (%)
Cardiovascular	Hypotension	0.8	5.2
	orthostatic effects	0.9	1.3
	chest pain	1.1	7.4
	angina	0.3	3.8
	edema	0.6	2.5
	palpitation	0.8	1.9
	rhythm disturbances	0.5	0.6
Gastrointestinal	Diarrhea	1.8	6.1
	Nausea	1.9	4.9
	Vomiting	1.1	2.4
	Dyspepsia	0.5	1.9
	Anorexia	0.4	1.4
	Constipation	0.2	0.8
	flatulence	0.3	0.5
Nervous System	Dizziness	4.4	14.2
	Headache	5.6	4.6
	Paresthesia	0.5	2.8
	Depression	0.7	1.1
	Somnolence	0.8	0.6
	Insomnia	0.3	2.4
	vertigo	0.2	0.2
Respiratory	Cough	3.0	6.4
	Dyspnea	0.4	7.4
	orthopnea	0.1	0.9
Dermatologic	Rash	1.0	5.0
	pruritus	0.5	1.4
Musculoskeletal	muscle cramps	0.5	2.2
	back pain	0.5	1.7
	leg pain	0.1	1.3
	shoulder pain	0.2	0.8
Other	asthenia/fatigue	2.7	7.1
	blurred vision	0.3	1.1
	fever	0.3	1.1
	flushing	0.3	0.3
	gout	0.2	1.7
	decreased libido	0.2	0.2
	malaise	0.3	1.1

Angioedema

Angioedema has been reported in patients receiving lisinopril (0.1%). In very rare cases, intestinal angioedema has been reported (See WARNINGS AND PRECAUTIONS, Immune, Angioedema).

Hypotension

In hypertensive patients, hypotension occurred in 0.8% and syncope occurred in 0.2% of patients. Hypotension or syncope was a cause for discontinuation of therapy in 0.3% of hypertensive patients (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).

In patients with CHF, hypotension occurred in 5.2% and syncope occurred in 1.7% of patients. Hypotension and dizziness were causes for discontinuation of therapy in 1.7% of these patients.

As shown in the ATLAS trial (see ACTION AND CLINICAL PHARMACOLOGY), high dose (≤ 35 mg) versus low dose (≤ 5 mg) treatment may predispose patients to hypotension-related symptoms such as: dizziness (18.9% versus 12.1%), syncope (7.0% versus 5.1%), and hypotension (10.8% versus 6.7%). These events were manageable and rarely led to treatment withdrawal. Therapy discontinuation rates for high versus low dose were: dizziness 0.3 and 0%, hypotension 0.8% and 0.6%, and for syncope 0.3% and 0.3%, respectively.

Treatment Following Acute Myocardial Infarction

In a controlled, open trial, involving 19,394 acute myocardial infarction patients (GISSI-3; see INDICATIONS AND CLINICAL USE - Treatment Following Acute Myocardial Infarction), comparing lisinopril alone, transdermal glycerol trinitrate, lisinopril and transdermal glycerol trinitrate, or control (no treatment), the most frequent in-hospital adverse events were as follows:

Event	Control n=4729	Lisinopril n=4713	Lisinopril + GTN n=4722	GTN Alone n=4731
Persistent Hypertension	3.6	8.8	9.3	3.9
Shock	2.5	2.8	2.2	1.9
Renal Dysfunction	1.1	2.4	2.4	1.1
Stroke	0.6	0.6	0.9	0.8
Re-Infarction	2.2	2.2	2.2	1.9
Hemorrhagic Events	1.2	1.3	1.1	0.9
Post-Infarction Angina	13.2	13.9	12.3	11.8
Ventricular Fibrillation	3.1	2.5	2.4	2.2
Sustained Ventricular Tachycardia	2.5	2.1	1.8	2.3
Atrial Flutter or Fibrillation	6.4	6.3	5.3	5.7
Complete Atrioventricular Block	2.4	2.9	2.5	2.1
Asystole	1.2	1.2	1.3	1.2
Intraventricular Septal Rupture	0.3	0.4	0.2	0.2
Papillary Muscle Rupture	0.3	0.4	0.5	0.4
Late CHF (>4 days)	4.5	4.5	4.2	4.2

Pediatric Patients (6-16 years old)

The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients.

Laboratory Test Findings

Serum Electrolytes

Hyperkalemia (see WARNINGS AND PRECAUTIONS).

Creatinine, Blood Urea Nitrogen

Increases in blood urea nitrogen (BUN) and serum creatinine, usually reversible upon discontinuation of therapy, were observed in 1.1% and 1.6% of patients respectively with essential hypertension treated with lisinopril alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis (see WARNINGS AND PRECAUTIONS). In patients with CHF on 2.5 to 20 mg lisinopril and concomitant diuretic therapy, reversible increases in BUN (14.5%) and serum creatinine (11.2%) were observed in approximately 12.0% of patients. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

As shown in the ATLAS trial (see ACTION AND CLINICAL PHARMACOLOGY), high dose (≤ 35 mg) versus low dose (≤ 5 mg) treatment may predispose patients to increased serum creatinine (9.9% versus 7.0%). This event was manageable and rarely led to treatment withdrawal. Therapy discontinuation rates due to increased serum creatinine for high versus low dose were 0.3% versus 0.4%, respectively.

Hematology

Decreases in hemoglobin and hematocrit (mean decreases of approximately 0.9g % and 0.6 vol %, respectively) occurred frequently in patients treated with lisinopril but were rarely of clinical importance in patients without some other cause of anemia. Rarely, hemolytic anemia has been reported.

Agranulocytosis and bone marrow depression, manifested as anemia, cytopenia or leukopenia, have been caused by ACE inhibitors, including lisinopril. Several cases of agranulocytosis and neutropenia have been reported in which a causal relationship to lisinopril cannot be excluded (see WARNINGS AND PRECAUTIONS, Hematologic, Neutropenia/Agranulocytosis).

Hepatic

Elevations of liver enzymes and/or serum bilirubin have occurred (see WARNINGS AND PRECAUTIONS - Patients with Impaired Liver Function).

Discontinuations

Overall, 1.0% of patients discontinued therapy due to laboratory adverse experiences, principally elevations in BUN (0.8%), serum creatinine (0.1%) and serum potassium (0.1%).

Post-Marketing Experience

The following undesirable effects have been observed and reported during treatment with lisinopril with the following frequencies: Very common ($\geq 10\%$), Common ($\geq 1\%$, $< 10\%$), uncommon ($\geq 0.1\%$, $< 1\%$), rare ($\geq 0.01\%$, $< 0.1\%$), very rare ($< 0.01\%$) including isolated reports.

Blood and lymphatic system disorders

Very rare: agranulocytosis, anemia, bone marrow depression, = hemolytic anemia (see WARNINGS AND PRECAUTIONS –

Neutropenia/Agranulocytosis), leucopenia, thrombocytopenia.

Endocrine disorders

Rare: inappropriate antidiuretic hormone secretion

Metabolism and nutrition disorders

Uncommon: hyperkalemia (see WARNINGS AND PRECAUTIONS – Hyperkalemia)

Rare: hyponatremia

Very rare: hypoglycaemia (see WARNINGS AND PRECAUTIONS – Diabetic Patients)

Nervous system and psychiatric disorders

Common: dizziness, headache.

Uncommon: hallucinations, mood alterations (including depressive symptoms), paresthesia, sleep disturbances, taste disturbance, vertigo.

Rare: mental confusions, olfactory disturbance.

Cardiac and vascular disorders

Common: orthostatic effects (including hypotension) (see WARNINGS AND PRECAUTIONS – Hypotension), syncope (frequency refers to congestive heart failure patient population, frequency in hypertensive patient population is “uncommon”).

Uncommon: myocardial infarction or cerebrovascular accident (both possibly secondary to excessive hypotension in high risk patients, (see WARNINGS AND PRECAUTIONS – Hypotension Following Acute Myocardial Infarction), palpitations, tachycardia.

Respiratory, thoracic and mediastinal disorders:

Common: cough

Uncommon: rhinitis

Very rare: bronchospasm, sinusitis

Gastrointestinal disorders

Common: diarrhea, vomiting.

Uncommon: abdominal pain, indigestion, nausea.

Rare: dry mouth.

Very rare: intestinal angioedema (See WARNINGS AND PRECAUTIONS – Angioedema and ADVERSE EVENTS – Angioedema), pancreatitis,.

Hepato-biliary disorders

Very rare: hepatitis – either hepatocellular or cholestatic, jaundice, hepatic failure. Very rarely it has been reported that in some patients the undesirable development of hepatitis has progressed to hepatic failure. Patients receiving lisinopril who develop jaundice or marked elevation of hepatic enzymes should discontinue lisinopril and receive appropriate medical follow-up (See WARNINGS AND PRECAUTIONS – Patients with Impaired Liver Function).

Skin and subcutaneous tissue disorders

Uncommon: rash, pruritus, hypersensitivity/angioedema: angioedema of the face, extremities, lips, tongue, glottis, and/or larynx (see WARNINGS AND PRECAUTIONS –Angioedema).

Rare: alopecia, psoriasis, urticaria.

Very rare: cutaneous pseudolymphoma, diaphoresis, erythema multiforme, pemphigus, Stevens-Johnson Syndrome, toxic epidermal necrolysis,.

A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leukocytosis. Rash, photosensitivity, or other dermatological manifestations may occur.

Renal and urinary disorders

Common: renal dysfunction.

Rare: acute renal failure, uremia.

Very rare: oliguria/anuria (see WARNINGS AND PRECAUTIONS – Renal Impairment).

Reproductive system and breast disorders

Uncommon: impotence.

General disorders and administration site conditions

Uncommon: asthenia, fatigue.

Investigations

Uncommon: increases in blood urea, increases in serum creatinine (see WARNINGS AND PRECAUTIONS – Renal Impairment), increases in liver enzymes (see WARNINGS AND PRECAUTIONS – Patients with Impaired Liver Function).

Rare: decreases in hemoglobin, decreases in hematocrit, increases in serum bilirubin (see WARNINGS AND PRECAUTIONS – Patients with Impaired Liver Function).

DRUG INTERACTIONS

Drug-Drug Interactions

Hypotension - Patients on Diuretic Therapy

Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of symptomatic hypotension with lisinopril can be minimized by discontinuing the diuretic prior to initiation of treatment with lisinopril and/or lowering the initial dose of lisinopril (See WARNINGS AND PRECAUTIONS, Hypotension; and DOSAGE AND ADMINISTRATION).

Hypotension - Patients on Antihypertensive Therapy

When lisinopril is given to patients already treated with other antihypertensive agents, further falls in blood pressure may also occur.

Dual Blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs

Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs or ACE inhibitors and aliskiren-containing drugs is contraindicated in patients with diabetes and/or renal impairment (see CONTRAINDICATIONS). Co-administration of ARBs, ACE inhibitors or aliskiren-containing drugs is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, decreased renal function (including acute renal failure), and hyperkalemia when compared to the use of a single RAS-acting agent (see WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) and Renal Impairment).

Potassium Supplements, potassium-sparing agents or potassium-containing salt substitutes and other drugs that may increase serum potassium levels

Since lisinopril decreases aldosterone production, elevation of serum potassium may occur. Potassium sparing diuretics such as spironolactone, triamterene or amiloride, or potassium supplements and other drugs that may increase potassium levels (e.g., heparin, co-trimoxazole) should be given only for documented hypokalemia and with caution and with frequent monitoring of serum potassium since they may lead to a significant increase in serum potassium. Potassium-containing salt substitutes should also be used with caution.

Agents Causing Renin Release

The antihypertensive effect of MYLAN-LISINOPRIL is augmented by antihypertensive agents that cause renin release (*e.g.* diuretics).

Agents Affecting Sympathetic Activity

Agents affecting sympathetic activity (*e.g.*, ganglionic blocking agents or adrenergic neuron blocking agents) may be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to lisinopril.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

In some patients with compromised renal function, lisinopril co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) may produce further renal function deterioration.

Indomethacin may diminish the antihypertensive efficacy of concomitantly administered MYLAN-LISINOPRIL.

Lithium Salts

As with other drugs which eliminate sodium, lithium elimination may be reduced. Therefore, the serum lithium levels should be monitored carefully if lithium salts are to be administered.

Gold

Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.

Antidiabetics

Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood glucose lowering effect with risk of hypoglycemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.

Tissue Plasminogen Activators

Concomitant treatment with tissue plasminogen activators may increase the risk of angioedema. Monitor patients for potential development of angioedema after initiation of tissue plasminogen activator infusion.

Mammalian Target of Rapamycin (mTOR) Inhibitors (*e.g.*, temsirolimus, sirolimus, everolimus)

Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema. Caution should be used when these drugs are used concomitantly (see WARNINGS, Angioedema).

Drug-Food Interactions

Since absorption of MYLAN-LISINOPRIL tablets (lisinopril) is not affected by food, the tablets may be administered before, during or after meals.

Drug-Herb Interactions

Interactions with herbal products have not been established.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Since absorption of MYLAN-LISINOPRIL tablets (lisinopril) is not affected by food, the tablets may be administered before, during or after meals. MYLAN-LISINOPRIL should be administered in a single daily dose. MYLAN-LISINOPRIL should be taken at the same time each day.

Dosage must be individualized and should be adjusted according to blood pressure response.

Recommended Dose and Dosage Adjustment

Essential Hypertension

In patients with essential hypertension, not on diuretic therapy, the usual recommended starting dose is 10 mg once a day. The usual dosage range is 10 to 40 mg per day, administered in a single daily dose. The antihypertensive effect may diminish toward the end of the dosing interval regardless of the administered dose, but most commonly with a dose of 10 mg daily. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in dose should be considered. The maximum dose used in long-term controlled clinical trials was 80 mg/day. If blood pressure is not controlled with MYLAN-LISINOPRIL alone, a low dose of diuretic may be added. Hydrochlorothiazide 12.5 mg has been shown to provide an additive effect. After the addition of diuretic, it may be possible to reduce the dose of MYLAN-LISINOPRIL.

Diuretic Treated Patients

In hypertensive patients who are currently being treated with a diuretic, symptomatic hypotension may occur occasionally following the initial dose of MYLAN-LISINOPRIL. The diuretic should be discontinued, if possible, for 2-3 days before beginning therapy with MYLAN-LISINOPRIL to reduce the likelihood of hypotension (see WARNINGS AND

PRECAUTIONS). The dosage of MYLAN-LISINOPRIL should be adjusted according to blood pressure response. If the patient's blood pressure is not controlled with MYLAN-LISINOPRIL alone, diuretic therapy may be resumed as described above.

If the diuretic cannot be discontinued, an initial dose of 5 mg should be used under medical supervision for ≥ 2 hours and until blood pressure has stabilized for \geq additional hour (see WARNINGS AND PRECAUTIONS, Hypotension; and DRUG INTERACTIONS).

A lower starting dose is required in the presence of renal impairment, in patients in whom diuretic therapy cannot be discontinued, patients who are volume and/or salt-depleted for any reason, and in patients with renovascular hypertension.

Dosage Adjustment in Renal Impairment

Dosage in patients with renal impairment should be based on creatinine clearance as outlined in the Table below:

Creatinine Clearance		Starting Dose mg/day
mL/s	mL/min	
0.50-1.17	31-70	5.0-10.0
0.17-0.50	10-30	2.5-5.0
<0.17 (including patients on dialysis)	<10 (including patients on dialysis)	2.5*

*Dosage and/or frequency of administration should be adjusted depending on the blood pressure response.

The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

Dosage in the Elderly

In general, blood pressure response and adverse experiences were similar in younger and older patients given similar doses of lisinopril. Pharmacokinetic studies, however, indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients so that dosage adjustments should be made with particular caution.

Renovascular Hypertension

Some patients with renovascular hypertension, especially those with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, may develop an increased risk of severe hypotension and renal insufficiency to the first dose of MYLAN-LISINOPRIL. In these patients, treatment should be started at low doses (2.5 or 5 mg), under close medical supervision. Thereafter, the dosage may be adjusted according to the blood pressure response. Doses should be carefully titrated.

Congestive Heart Failure

MYLAN-LISINOPRIL is to be used in conjunction with diuretics, and where appropriate, digitalis. Therapy must be initiated under close medical supervision, usually in a hospital. Blood pressure and renal function should be monitored, both before and during treatment with

MYLAN-LISINOPRIL, because severe hypotension and, more rarely, consequent renal failure have been reported (see WARNINGS AND PRECAUTIONS, Hypotension; and WARNINGS AND PRECAUTIONS, Renal Impairment).

Initiation of therapy requires consideration of recent diuretic therapy and the possibility of severe salt/volume depletion. If possible, the dose of diuretic should be reduced before beginning treatment.

The recommended initial dose is 2.5 mg per day. The MYLAN-LISINOPRIL dose should be increased:

- by increments of ≤ 10 mg,
- at intervals of ≥ 2 weeks, up to a maximum of 35 mg once daily. Dose adjustment should be based on the individual patient's tolerance and clinical response.

Treatment Following Acute Myocardial Infarction

Treatment with MYLAN-LISINOPRIL may be started as early as within 24 hours following the onset of symptoms in hemodynamically stable patients. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, ASA and beta-blocker(s) (see INDICATION AND CLINICAL USE - Treatment Following Acute Myocardial Infarction).

The first dose of MYLAN-LISINOPRIL is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily thereafter.

Patients with a low systolic blood pressure (between 100 and 120 mm Hg) when treatment is started or during the first 3 days after the infarct should be given a lower dose - 2.5 mg orally. Treatment with MYLAN-LISINOPRIL must not be initiated in patients who are at risk of serious hemodynamic deterioration (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension Following Acute Myocardial Infarction). After three days, if hypotension occurs (systolic blood pressure ≤ 100 mm Hg), a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure <90 mm Hg for >1 hour), MYLAN-LISINOPRIL should be withdrawn.

Renal function should be assessed before and during therapy with MYLAN-LISINOPRIL (see WARNINGS AND PRECAUTIONS, Renal Impairment).

Dosing should normally continue for 6 weeks. At that time, patients with signs or symptoms of heart failure should continue with MYLAN-LISINOPRIL (see DOSAGE AND ADMINISTRATION - Congestive Heart Failure).

MYLAN-LISINOPRIL is compatible with intravenous or transdermal glyceryl trinitrate.

Pediatric Patients (6-16 years old)

For patients who can swallow tablets, the dose should be individualized according to patient profile and blood pressure response. The recommended initial dose is 2.5 mg in patients 20 to <50 kg and 5 mg in patients ≥ 50 kg. MYLAN-LISINOPRIL is given once daily. The dosage should be adjusted according to the needs of the patient to a maximum of 20 mg daily in patients 20 to <50 kg and 40 mg in patients ≥ 50 kg (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics, Pharmacokinetics).

MYLAN-LISINOPRIL is not recommended in pediatric patients <6 years or with GFR <30 mL/min/1.73 m² (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics, Pharmacokinetics).

Missed Dose

If a dose of this medication is missed, it is not necessary to make up the missed dose. Skip the missed dose and continue with the next scheduled dose. Do not double doses.

Administration

Since absorption of MYLAN-LISINOPRIL tablets (lisinopril) is not affected by food, the tablets may be administered before, during or after meals. MYLAN-LISINOPRIL should be administered in a single daily dose. MYLAN-LISINOPRIL should be taken at the same time each day.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

Overdose symptoms include severe hypotension, electrolyte disturbances, and renal failure. Overdosed patients should be kept under very close observation. Therapeutic measures depend on the nature and severity of symptoms. Measures to prevent absorption and methods to speed elimination should be employed. If severe hypotension occurs, place the patient in the shock position and infuse intravenous normal saline immediately. Vasopressors including angiotensin II may be considered if fluid replacement is inadequate or contraindicated. Circulating lisinopril may be removed by hemodialysis. Avoid high-flux polyacrylonitrile dialysis membranes (see WARNINGS AND PRECAUTIONS, Anaphylactoid Reactions during membrane exposure). Serum electrolytes and creatinine should be monitored frequently.

ACTION AND CLINICAL PHARMACOLOGY

Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which is used in the treatment of hypertension, congestive heart failure and following myocardial infarction in hemodynamically stable patients.

Mechanism of Action

Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which catalyzes the conversion of angiotensin I to the pressor substance, angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release) and decreased aldosterone secretion. Although the latter decrease is small, it results in a small increase in serum potassium. In patients treated with lisinopril and a thiazide diuretic there was essentially no change in serum potassium (see WARNINGS AND PRECAUTIONS).

ACE is identical to kininase II. Thus, lisinopril may also block the degradation of bradykinin, a potent vasodilator peptide. However, the role that this plays in the therapeutic effects of lisinopril is unknown.

While the mechanism through which lisinopril lowers blood pressure is believed to be primarily the suppression of the renin-angiotensin-aldosterone system (RAAS), lisinopril also lowers blood pressure in patients with low-renin hypertension.

Pharmacodynamics

Hypertension

Adults: Administration of lisinopril to patients with hypertension results in a reduction of both supine and standing blood pressure. Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure. In most patients studied, after oral administration of an individual dose of lisinopril, the onset of antihypertensive activity is seen at one hour with peak reduction of blood pressure achieved by 6 hours. Although an antihypertensive effect was observed 24 hours after dosing with recommended single daily doses, the effect was more consistent and the mean effect was considerably larger in some studies with doses of ≥ 20 mg than with lower doses. However, at all doses studied, the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was 6 hours after dosing. On occasion, achievement of optimal blood pressure reduction may require 2 to 4 weeks of therapy.

Pediatrics (6-16 years old): In a clinical study involving 115 hypertensive pediatric patients 6 to 16 years of age, patients who weighed < 50 kg received either 0.625, 2.5, or 20 mg of lisinopril daily and patients who weighed ≥ 50 kg received either 1.25, 5, or 40 mg of lisinopril daily. At the end of 2 weeks, lisinopril administered once daily lowered trough blood pressure in a dose-dependent manner with consistent antihypertensive efficacy demonstrated at doses > 1.25 mg (0.02 mg/kg). This effect was confirmed in a withdrawal phase, where the diastolic pressure rose

by about 9 mmHg more in patients randomized to placebo than it did in patients who were randomized to remain on the middle and high doses of lisinopril. The dose-dependent antihypertensive effect of lisinopril was consistent across several demographic subgroups: age, Tanner stage, gender, race. In this study, lisinopril was generally well-tolerated.

Adults: In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in 9 hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not large.

When lisinopril is given together with thiazide-type diuretics, its blood pressure lowering effect is approximately additive.

Congestive heart failure

Administration of lisinopril to patients with congestive heart failure reduces afterload and preload of the heart, resulting in an increase in cardiac output, without reflex tachycardia. Exercise tolerance is improved.

In the Assessment of Treatment with Lisinopril and Survival Study (ATLAS) higher doses of lisinopril ≤ 35 mg once daily reduced the risk of the combined outcome of mortality and hospitalization in patients with chronic congestive heart failure (CHF). The ATLAS study was an international, multicenter, double-blind, parallel group clinical trial which evaluated the effects of low doses, 2.5 mg-5.0 mg, versus high doses, 32.5 mg-35.0 mg lisinopril on mortality and morbidity in patients with chronic CHF. A total of 1596 patients were randomized into the low dose and 1568 into the high dose groups. Patients entered into the ATLAS study were NYHA Class II, III, or IV, were treated with diuretics for at least 60 days prior to entry into the study, and had a left ventricular ejection fraction (LVEF) $\leq 30\%$. Class II patients were eligible only if they were hospitalized or received emergency room treatment in the previous 6 months. Prior treatment with ACE inhibitors and digoxin was permitted, and patients were permitted routine therapies, other than ACE inhibitors, for the duration of the study. The median follow-up period was 46 months. The protocol excluded patients with recent cardiac surgery, unstable coronary artery disease, unstable ventricular arrhythmias, unstable CHF, or a non-CHF disorder that may have limited survival during the course of the trial. Overall, 77% of patients were NYHA class III; 89% had previous ACE inhibitor treatment. For the principal secondary endpoint, all-cause mortality and all-cause hospitalization, high dose lisinopril was associated with an 11.6% ($p=0.002$) risk reduction over low dose (2.5 and 5 mg). High dose lisinopril was also associated with an 8.4% risk reduction in all-cause mortality and cardiovascular hospitalizations ($p=0.036$). The total number of hospitalizations per patient for heart failure was reduced by 23.2% ($p=0.002$).

Pharmacokinetics

Absorption:

After oral administration of lisinopril, peak serum concentrations of lisinopril occur within approximately 7 hours, although patients with recent myocardial infarction have demonstrated an increase in time to peak serum concentration to about 8 to 10 hours. Declining serum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not bind serum proteins other than ACE.

Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the extent of absorption of lisinopril is approximately 25%, with large inter-subject variability (6-60% at all doses tested (5-80 mg)).

Lisinopril absorption is not influenced by the presence of food in the gastrointestinal tract.

Following multiple doses of lisinopril, the effective half-life of accumulation is 12 hours.

Adults: In a study in elderly healthy subjects (≥ 65 years), a single dose of lisinopril 20 mg produced higher serum concentrations and higher values for the area under the plasma curve (AUC) than those seen in young healthy adults given a similar dose. In another study, single daily doses of lisinopril 5 mg were given for 7 consecutive days to young and elderly healthy volunteers and to elderly patients with CHF. Maximum serum concentrations of lisinopril on Day 7 were higher in the elderly volunteers than in the young, and still higher in the elderly patients with CHF. Renal clearance of lisinopril was decreased in the elderly, particularly in the presence of CHF.

Impaired renal function decreases elimination of lisinopril. This decrease becomes clinically important when the glomerular filtration rate (GFR) is <below 30 mL/min (see PRECAUTIONS, Renal Impairment, and DOSAGE AND ADMINISTRATION).

Lisinopril can be removed by dialysis.

Pediatrics (6-16 years old): The pharmacokinetics of lisinopril were studied in 29 pediatric hypertensive patients between 6 years and 16 years with GFR is >30 mL/min/1.73 m². After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults. The typical value of lisinopril oral clearance (systemic clearance/absolute bioavailability) in a child weighing 30 kg is 10 L/h, which increases in proportion to renal function.

Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.

Hepatic Insufficiency:

No data is available (see WARNINGS AND PRECAUTIONS, Hepatic / Biliary / Pancreatic).

Genetic Polymorphism:

No data is available.

STORAGE AND STABILITY

Store between 15°C and 30°C.

DOSAGE FORMS, COMPOSITION AND PACKAGING

MYLAN-LISINOPRIL is supplied as 5 mg, 10 mg and 20 mg tablets for oral administration. In addition to the active ingredient lisinopril, each tablet contains the following inactive ingredients: corn starch, dibasic calcium phosphate, magnesium stearate, mannitol 60, talc and red iron oxide #30.

MYLAN-LISINOPRIL 5 mg tablets are a pink, oval, biconvex tablet, with “G” over “L5” on one side and scored on the one side. Available in bottles of 100 and 500 tablets.

MYLAN-LISINOPRIL 10 mg tablets are pink, oval, biconvex tablet, with “G” over “L10” on one side and plain on the other side. Available in bottles of 100 and 500 tablets.

MYLAN-LISINOPRIL 20 mg tablets are pink, oval, biconvex tablet, with “G” over “L20” on one side and plain on the other side. Available in bottles of 100 and 500 tablets.

PART II: SCIENTIFIC INFORMATION


PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Lisinopril

Chemical name: (S)-1-[N²-(1-Carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate
L-Proline, 1-[N²-(1-carboxy-3-phenylpropyl)-L-lysyl]-, dihydrate, (S)-;
1-[N²-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl]-L-proline dehydrate

Structural formula:



Molecular formula: $C_{21}H_{31}N_3O_5 \cdot 2H_2O$

Molecular mass: 441.52 g/mol

Description: Lisinopril is a white to off-white, crystalline powder. It is very soluble in water, sparingly soluble in methanol and practically insoluble in ethanol.

pH:

The pH is about 5.1 in a 1% aqueous solution at room temperature.

pKa:

Aqueous acidic/base potentiometric titration at 25°C yielded four pKa values:

$$pK_{a1} = 2.5$$

$$pK_{a2} = 4.0$$

$$pK_{a3} = 6.7$$

$$pK_{a4} = 10.1$$

CLINICAL TRIALS

Comparative Bioavailability Studies

Bioequivalence studies were performed to compare MYLAN-LISINOPRIL Tablets against Zestril[®] Tablets. Comparative bioavailability data have been submitted for the 5 mg and 20 mg strength. The studies performed were two-way, crossover, blinded, single-dose, fasting, bioequivalence studies of MYLAN-LISINOPRIL tablets versus Zestril[®] Tablets in 36 normal healthy non-smoking male subjects.

The pharmacokinetic data from these studies are presented in the following pages.

Lisinopril (1 x 5 mg) From measured data Uncorrected for potency Geometric Mean Arithmetic mean (CV %)				
Parameter	TEST*	REFERENCE [†]	% Ratio of Geometric Means	Confidence Interval (90%)
AUC ₀₋₇₂ (ng·hr/mL)	303.66 323.35 (35.34)	301.84 325.70 (39.23)	99.72%	92.46% to 107.55%
AUC ₁ (ng·hr/mL)	338.53 356.62 (32.58)	341.07 361.30 (34.73)	99.25%	93.00% - 105.93%
C _{max} (ng/mL)	17.59 19.44 (42.37)	17.40 19.54 (47.86)	101.08%	91.48% to 111.69%
T _{max} [§] (hr)	8.00 (6.00-10.00)	8.00 (6.00-10.00)		
T _{1/2} (hr)	23.71 (21.47)	24.73 (34.42)		

* MYLAN-LISINOPRIL 5 mg Tablets (Mylan Pharmaceuticals ULC, Canada).

[†] Zestril[®] 5 mg Tablets (AstraZeneca Canada Inc.) was purchased in Canada.

[§] Expressed as the median (range) only.

^{||} Expressed as the arithmetic mean (CV%) only.

Lisinopril (1 x 20 mg) From measured data Uncorrected for potency Geometric Mean Arithmetic mean (CV %)				
Parameter	TEST*	REFERENCE†	% Ratio of Geometric Means	Confidence Interval (90%)
AUC ₀₋₇₂ (ng·hr/mL)	1256.27 1341.94 (36.04)	1331.95 1399.56 (31.74)	93.45%	84.26% to 103.65%
AUC ₁ (ng·hr/mL)	1284.47 1364.49 (34.80)	1333.55 1398.08 (31.25)	96.33%	87.52% to 106.02%
C _{max} (ng/mL)	87.90 94.88 (37.69)	91.32 96.68 (32.89)	96.25%	85.92% to 107.82%
T _{max} § (hr)	7.50 (5.00-9.00)	7.00 (4.00-9.00)		
T _{1/2} (hr)	13.50 (30.33)	13.08 (32.11)		

* MYLAN-LISINOPRIL 20 mg Tablets (Mylan Pharmaceuticals ULC, Canada).

† Zestril® 20 mg Tablets (AstraZeneca Canada Inc.) was purchased in Canada.

§ Expressed as the median (range) only.

|| Expressed as the arithmetic mean (CV%) only.

DETAILED PHARMACOLOGY

Mechanism of Action

Study	Species/Strain	Number of Animals/ Group	Route	Dose	Results
<i>in vitro</i> ACE inhibitory activity*	hog plasma		<i>in vitro</i>		IC ₅₀ = ± 0.5 nM
augmentation of contractile response to bradykinin	guinea pig ileum	7 segments	<i>in vitro</i>		AC ₅₀ = 1.6 nM
<i>in vivo</i> ACE inhibition in the rat**	male Sprague/Dawley	8	i.v.		ID ₅₀ = 2.3 (1.7-3.1) mcg/kg
duration of ACE inhibitory activity of lisinopril in rats**	male Sprague/Dawley	4	i.v.	3 & 10 mcg/kg	Duration approx. 110 min.
<i>in vivo</i> ACE inhibitory activity of lisinopril in conscious rats**	Sprague/Dawley	3 - 5	p.o.	0.03-3.0 mg/kg (single dose)	Duration of at least 360 mins.
<i>in vivo</i> ACE inhibition in anesthetized dogs**	Mongrel	6	i.v.	1-30 mcg/kg	ID ₅₀ = 6.5 mcg/kg
<i>in vivo</i> ACE inhibitory activity of lisinopril in conscious dogs**	Mongrel	3	p.o.	0.05-1.0 mg/kg (single dose)	Duration of action of between 6-24 hrs.

* Inhibition of enzymatic activity of hog plasma ACE using ¹⁴C labeled substrate.

** Blockage of functional (pressor) response to A1 challenge.

Effects on Blood Pressure

Study	Species/Strain	Number of Animals/Group	Route	Dose	Results
antihypertensive activity in renal hypertensive dogs (single doses)	Mongrel	3	p.o.	0.3 mg/kg with and without hydrochlorothiazide	After 2 hours: Lisinopril alone: 5% reduction in mean systolic pressure vs pretreatment. Lisinopril + HCTZ = 11% reduction in mean systolic pressure vs pretreatment.
antihypertensive activity in rats on a sodium-deficient diet	Male Sprague/Dawley	5	p.o.	0.03-3.0 mg/kg daily for 4 days	After 2 hours: 11% reduction in mean systolic pressure vs pretreatment at 1 mg/kg. 22% reduction in mean systolic pressure vs pretreatment at 3 mg/kg. Consistent response over 4 days.
antihypertensive activity in 2 kidney Grollman hypertensive rats (single doses)	Male Sprague/Dawley	6 – 7	p.o.	1 & 3 mg/kg	At 2 hours: approx. 6% reduction in mean systolic pressure vs pretreatment with the antihypertensive effect lasting up to 24 hours.
antihypertensive activity in spontaneously hypertensive rats with and without hydrochlorothiazide	SH rats	3 – 6	p.o.	1.25 mg/kg HCTZ = 50 mg/kg daily for 3 days	Enhancement of hypotensive activity over 3-5 days. 2 hours after drug administration, lisinopril alone reduced the average mean arterial pressure from 198 to 161 mm Hg. In combination with HCTZ the average mean arterial pressure was reduced from 202 to 132 mm Hg.
antihypertensive activity in spontaneously hypertensive rats (single doses)	SH rats	3 – 9	p.o. & i.v.	0.1-20 mg/kg	Slight fall in blood pressure at 0.312-5 mg/kg p.o. Pronounced fall at 20 mg/kg p.o. and 0.1 mg/kg i.v. with statistically significant reductions being observed for the majority of time points between 1/2-18 hours.

MICROBIOLOGY

Not applicable.

TOXICOLOGY

Acute Toxicity of Lisinopril

LD₅₀ Values

Route	Species	Sex	LD₅₀ (g/kg)
Oral	Mouse	male	>20
	Mouse	female	>20
	Rat	male	>20
	Rat	female	>20
	Dog	male	>6
	Dog	female	>6
Intravenous	Mouse	male	>10
	Mouse	female	>10
Intraperitoneal	Rat	male	>10
	Rat	female	>10

Signs of toxicity: Following oral administration to mice decreased activity and one male death (1/10) occurred. No signs of toxicology occurred in rats after oral administration. Dogs given 6 g/kg had transient diarrhea and increases in serum urea nitrogen. Intravenous administration to mice produced bradypnea, ataxia, clonic convulsions, exophthalmia, and tremors. After intraperitoneal administration in rats, ataxia and one female death (1/10) occurred. No signs of toxicology or death occurred in the males.

Subacute/Chronic Toxicology

Species	Duration	No. of Animal/Group	Route	Dose mg/kg/day	Effects
Rat	2-week	10 F + 10 M	Oral	3,10,30	At all doses, decreases of 2 to 16% in weight gain and 12 to 14% in heart weights were observed in female rats.
Rat	3-month with 1-month Interim	25 F + 25 M	Oral	3,10,30	At all doses, increased serum urea nitrogen values (up to approximately 2-fold) and decreased heart weights (7 to 10%) were observed in female rats. At 10 and 30 mg respectively weight gain decreased 11 to 14% in males. An increased incidence of focal erosions of the gastric mucosa and focal renal tubular basophilia were also seen.
Rat	1-Year with 6-Month Interim	25 F + 25 M	Oral	2,5,10,30,90 ^a	At all doses, a decrease in weight gain (up to 16%) was observed. Serum urea nitrogen increased up to 4-fold; serum sodium decreased (average down to 3 mEq/L) and serum potassium increased (average up to 0.5 mEq/L). At 2, 5, 10 and 30 mg heart weight decreased; at 5, 10 and 30 mg, kidney weight increased; and at 5, 10, 30 and 90 mg, renal tubular basophilia increased. At 10, 30 and 90 mg, focal interstitial nephritis was observed.
Rat	3-Month with a 1- Month Interim and a 1- Month Recovery	30 F + 30 M	Oral	3,30,300, 3000	At all doses, weight gain decreased by 5 to 11%, and increases were observed in serum urea nitrogen (up to approximately 3-fold) and serum potassium (average up to 0.4 mEq/L). At 30, 300 and 3000 mg there was an increased incidence of focal tubular basophilia persisted in rats given 300 or 3000 mg/kg/day.
Rat	1-Month	15 F + 15 M	Oral	30,60 30,60 (with saline)	Saline supplementation prevented decreased weight gain and elevations in serum urea nitrogen at 30 and 60 mg. Decreases in cardiac weight at 30 and 60 mg, were suppressed by saline supplementation in males at 30 mg. At 30 and 60 mg renal changes produced due to a low salt diet, (renal tubular degeneration and renal tubular basophilia) were prevented by saline supplementation. Mild gastric erosions or necrotic changes were seen in 1 or 2 of 30 rats given 30 or 60 mg. These gastric changes were not seen in saline supplemented animals given these doses; however, the relationship of amelioration due to saline is uncertain because of the low incidence of this change, which is also occasionally seen in untreated animals.

Species	Duration	No. of Animal/Group	Route	Dose mg/kg/day	Effects
Rat	5 Days 6 Day Recovery	8 M	Oral	5, 300	Consumption of 2% saline increased during treatment at 5 mg and on Days 2 to 4 post-treatment at 300 mg.

^a Dosing terminated Week 11, rats killed Week 27.

Subacute/Chronic Toxicology (continued)

Species	Duration	No. of Animal/Group	Route	Dose mg/kg/day	Effects
Dog	2-week	3 F + 3 M	Oral	3,10,30	At 30 mg, slight mineralization of the papilla muscle of the heart was seen in 1 of 6 dogs.
Dog	3-Month with 1-Month Interim	5 F + 5 M	Oral	3,10,30	At 10 mg, hemoglobin concentration, hematocrit, and erythrocyte count decreased in 2 dogs. Marked increases in serum urea nitrogen and creatinine were observed in 2 of 10 dogs. One of these dogs had marked renal tubular degeneration and ulcers of the tongue, gums, and gastric pyloric mucosa related to uremia. At 30 mg there was an increase in serum urea nitrogen (average up to 2-fold) and a decrease in serum sodium (down to 4 mEq/L) and serum chloride (down to 3 mEq/L). At 10 and 30 mg, average cardiac weight decreased (13 to 15%).
Dog	1-Year with 6-Month Interim	5 F + 5 M	Oral	3,5,15	At 15 mg, increases were observed in serum urea nitrogen (less than 2-fold). Decreases in serum sodium (average down to 2 mEq/L) and increases in serum potassium (average up to 0.5 mEq/L) occurred at all doses.
Dog	18-Day	3 F + 3 M	Oral	60/90 with and without saline	Saline supplementation prevented increases in serum urea nitrogen in dogs given 60 mg for 8 days followed by 90 mg for 8 or 9 days.
Dog	7-Day	4 F + 4 M	i.v.	60,90	Decreases in blood pressure and increases in serum urea nitrogen occurred in dogs given 60 or 90 mg/kg/day. Supplementation with physiologic saline (25 mL/kg one hour prior to dosing and 4 hours after dosing) prevented these changes. Increased serum potassium (average up to 0.6 mEq/L) and decreased serum chloride (average down to 0.4 mEq/L) values were seen in both supplemented and unsupplemented animals.
Dog	1-Month	2 F + 2 M	Oral	3,30,300 and 1000	At 30 mg or greater, BUN increased and specific gravity of the urine decreased. Hyperplasia of renal epithelial cells was observed and deaths occurred. Dogs that died had dilation of distal renal tubules and fatty degeneration epithelium. No drug-related effects were observed at 3 mg.

Subacute/Chronic Toxicology (continued)

Species	Duration	No. of Animal/Group	Route	Dose mg/kg/day	Effects
Dog	3-Month with 1-Month Recovery (high dose)	Control 5 M + 5 F 3, 10 & 30 mg/kg/day 3 M + 3 F 100 mg/kg/day 8 M + 8 F Recovery Control 2 M + 2 F 100 mg/kg/day 5 M + 5 F	Oral	3,10,30 and 100	Eight of 16 dogs given 100 mg died or were killed because of poor physical condition. One of 6 dogs given 30 mg was killed because of poor physical condition. At 10 mg or greater increased BUN and dilation of renal tubules was seen. Fatty degeneration of renal tubular epithelium occurred at the 2 highest dosage levels. The changes are reversible as only slight dilation of renal tubules was present in some animals given 100 mg after 4 weeks of recovery.
Rabbit	2-Weeks	6 F	Oral	15 (1,6 & 13 doses) with and without saline	Renal tubular basophilia and renal tubular dilation (considered sequela to necrosis) were seen after 6 and 13 doses in unsupplemented rabbits. Two supplemented rabbits (6 doses) also had the same renal lesion. One rabbit drank very little saline and had increases in BUN, creatinine, and potassium. Increases in these parameters were seen in unsupplemented animals after 1, 6, and 13 doses.

Teratology Studies

Species	No. of Animal/Group	Dose mg/kg/day	Route	Duration of Dosing	Results
Mice	25	100,300, 1000, 1000 with saline	Oral	Day 6 through Day 15 of gestation	No teratogenic effect was observed. There was an increased incidence of resorptions in all unsupplemented groups (no increase in serum urea nitrogen).
Rat	35	30,100, 300, 300 with saline	Oral	Day 6 through Day 17 of gestation	No teratogenic effect was observed. Maternal effect was observed. Maternal weight gain decreased in all unsupplemented groups. The open field behavioral test (measure of spontaneous activity) showed increased activity in Week 5 postpartum F1 females at 300 mg with and without saline, but only in 300 mg with saline females in Week 6. When the open field test was repeated in males and females given 300 mg with and without saline in Week 11, no increase in activity was seen.
Rabbit (New Zealand)	18	0.1, 0.3, 1.0 all groups with saline	Oral	Day 6 through Day 18 of gestation	No teratogenic effect was observed. At all doses there was an increased incidence of incomplete ossification (sternebrae, metacarpals, forefoot phalanges, pelvic bones and tali and/or calcanea) which was considered to represent a fetotoxic effect. At 1 mg one rabbit had a high incidence of resorptions.
Rabbit (New Zealand)	18	0.031, 0.125, 0.5	Oral	Day 6 through Day 18 of gestation	No fetotoxicity, nor embryotoxicity was observed at maternotoxic doses. At 0.125 and 0.5 mg maternal deaths, decreased maternal weight gain and food consumption, as well as increases in BUN, creatinine and potassium were seen. In addition, doses of 0.5 mg produced decreases in serum sodium and chloride diffuse distention of the renal distal tubules and degeneration of renal tubules.

Fertility and Late Gestation and Lactation with Postnatal Evaluation Studies

Species	No. of Animal/Group	Route	Dose mg/kg/day	Duration of Dosing	Results
Rat	24 F & 24 M	Oral	30,100, 300 300 with saline	Males were dosed for 78 days prior to mating and females from 15 days prior to mating until sacrifice on Day 20 of gestation	Weight gain was reduced in unsupplemented males at all doses and during gestation in unsupplemented females. No effects on fertility and no signs of teratogenicity were observed. There was an increase in F1 pup deaths (3 to 8% vs control 1%) Day 1 to 7 postpartum in 100 and 300 mg (saline and nonsaline) groups. Decreased mean F1 pup weight (3 to 7% less than controls) on Day 0 postpartum was seen in all unsupplemented groups.
Rat	20F	Oral	30,100, 300 300 with saline	Day 15 of gestation through Day 21 postpartum	On Days 2 to 7 postpartum there was an increased number of dead pups (8 to 10% vs. Control 0%). On Day 21 postpartum, a decrease in pup weights (8% less than controls) was observed in the unsupplemented 100 and 300 mg groups. There was no effect in the supplemented group. Pup development was not altered.

Genotoxicity Studies

Study	Test System	Dose	Results
<u>Mutagenesis</u> Microbial mutagen with and without metabolic activation	<u>Salmonella typhimurium</u> TA1535, TA1537, TA98, TA100 <u>Escherichia coli</u> WP2, WP2 uvrA	≤ 2000 µg/plate ≤ 10 mg/plate	Negative for mutagenic potential.
<u>In vitro</u> V-79 mammalian cell mutagenesis with and without metabolic activation	Chinese Hamster Lung Cell	≤ 10 mM (4.42 mg/mL)	Negative for mutagenic potential.
<u>DNA Damage</u> <u>In vitro</u> alkaline elution	Rat Hepatocyte	≤ 30 mM (13.25 mg/mL)	Negative for induction of DNA single strand breaks.
<u>Chromosomal Evaluation</u> <i>In vitro</i> chromosomal aberration assay with and without metabolic activation	Chinese Hamster Ovary	≤ 30 mM (13.25 mg/mL)	Negative for induction of chromosomal aberration.
<i>In vivo</i> chromosomal aberration assay	Bone Marrow Cells of Male Mice	≤ 5000 mg/kg	Negative for increases in chromosomal aberrations.

Carcinogenicity Studies

Species	Duration of Dosing	No. of Animal/Group	Route	Dose mg/kg/day	Results
Mice Cri:CD-1 (ICR) BR	92 weeks	50 F & 50 M	Oral	15,45,135 mg/kg/day	No evidence of carcinogenic effect was observed. Decreased weight gain (7 to 15%) was seen in females at 135 mg. A greater incidence and severity of chronic nephritis in females and males given 45 and 135 mg was also seen.
Rats Cri:CD (SD) BR	105 weeks	50 F & 50 M	Oral	10,30,90 mg/kg/day	No evidence of carcinogenic effect was observed. Decreased weight gain (5 to 14%) in male drug-treated rats during the first 67 weeks of the study was observed. Focal sacculations of the retinal vessels was more prevalent in rats given 30 or 90 mg than in controls in Drug Week 100. An increased incidence of renal tubular hypertrophy in drug-treated males was seen at termination of the study (1 mg was considered the no-effect dose for this change in males based on an additional 105 week study at 1, 3, and 10 mg/kg/day). An increased incidence of chronic nephritis in drug-treated females (10 mg is the no-effect dose based on an additional 105 week study at 1, 3, and 10 mg/kg/day) was observed.

REFERENCES

1. Ajayi AA, Campbell BC, Howie CA, Reid JL.
Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. *J Hypertens* 1985;3:47-53.
2. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, Jones KH, Feber F, Abrams WB, Gavras H, Brunner HR.
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. *Clin Pharmacol Ther* 1981;29:665-670.
3. Biollaz J, Schelling JL, Jacot des Combes B, Brunner DB, Desponds G, Brunner HR, Ulm EH, Hichens M, Gomez HJ.
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers: Relationship between plasma drug levels and the renin angiotensin system. *Br J Clin Pharmacol* 1982;14:363-368.
4. Brunner DB, Desponds G, Biollaz J, Keller I, Feber F, Gavras H, Brunner HR, Schelling JL.
Effect of a new angiotensin converting enzyme inhibitor MK-421 and its lysine analogue on the components of the renin system in healthy subjects. *Br J Clin Pharmacol* 1981;11:461-467.
5. Bussien JP, Waeber B, Nussberger J, Gomez HJ, Brunner HR.
Once-daily lisinopril in hypertensive patients: Effect on blood pressure and the renin-angiotensin system. *Current Therapeutic Research* 1985;37:342-351.
6. Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, Lewis GRJ, Maranhao MFL, Myburgh DP, Schuster P, Sialer S, Simon H, Stephens JD, Watson RDS.
Placebo-controlled study of lisinopril in congestive heart failure: A multicenter study. *J Card Pharmacol* 1987;9(Suppl 3):S82-S88.
7. Cirillo VJ, Gomez HJ, Salonen J, Salonen R, Rissanen V, Bolognese JA, Nyberg R, Kristianson K.
Lisinopril: dose-peak effect relationship in essential hypertension. *Br J Clin. Pharmac* 1988;25:533-538.
8. Derkx FHM, Millar JA, Reid JL, Schalekamp MADH.
Pharmacodynamics of MK421 (enalapril) and its lysine analogue MK521. *Progress in Pharmacol* 1984;5:93-105.
9. Donohue JF, Kelly J, Laher MS, Doyle GD.

- Lisinopril in the treatment of hypertensive patients with renal impairment. *Am J Med* 1988;85(Suppl 3B):31-34.
10. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, Powers E, Rich S, Hackshaw B, Chiaramida A, Rouleau JL, Fisher MB, Pigeon J, Rush JE. Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. *J Am Coll Cardiol* 1989;13(6):1240-1246.
 11. GISSI-3 Gruppo Italiano per lo Studio della Sopravvivenza ell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. *Lancet* 1994;343:1115-1122.
 12. Laher MS, Natin D, Rao SK, Jones RW, Carr P. Lisinopril in elderly patients with hypertension. *J Card Pharmacol* 1987;9(Suppl 3) S69-S71.
 13. Massie BM, Cleland GFJ, Armstrong PW, Packer M, Poole-Wilson PA, Ryden L, for the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial investigators. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. *Journal of Cardiac Failure* 1998;4:3-8.
 14. Millar JA, Derkx FHM, McLean K, Reid JL. Pharmacodynamics of converting enzyme inhibition: The cardiovascular endocrine and autonomic effects of MK-421 (enalapril) and MK-521. *Br J Clin Pharmacol* 1982;14:347-355.
 15. Myers MG, Carruthers SG, Leenen FHH, Haynes RB. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. *CMAJ* 1989;140:1141-1146.
 16. Powers ER, Chiaramida A, DeMaria AN, Giles TD, Hackshaw B, Hart W, Haugland M, Johnston R, Katz R, Kirlin P, McCall M, Mohiuddin S, Rich S, Sullivan JM, Wolfson P and Co-investigators. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. *J Card Pharmacol* 1987;9(Suppl 3):S82-S88.
 17. Rotmensch HH, Vlasses PH, Swanson BN, Irvin JD, Harris KE, Merrill DD, Ferguson RD. Antihypertensive efficacy of once daily MK-521, a new nonsulphydryl angiotensin-converting enzyme inhibitor. *Am J Cardiol* 1984;53(1):116-119.
 18. Product Monograph for Zestril[®] (lisinopril tablets, USP) 5, 10 and 20 mg tablets, AstraZeneca Canada Inc. Date of Revision: , February 24 2016, Control No. 187922 .

IMPORTANT: PLEASE READ

PART III: CONSUMER INFORMATION

PrMYLAN-LISINOPRIL (Lisinopril Tablets, USP)

Read this carefully before you start taking MYLAN-LISINOPRIL and each time you get a refill. This leaflet is a summary and will not tell you everything about MYLAN-LISINOPRIL. Talk to your doctor, nurse, or pharmacist about your medical condition and treatment and ask if there is any new information about MYLAN-LISINOPRIL.

ABOUT THIS MEDICATION

What the medication is used for:

Your doctor has prescribed you MYLAN-LISINOPRIL for one of the following reasons:

- Your blood pressure is too high (hypertension);
- You have a heart condition known as heart failure, where the heart does not pump your blood around your body as well as it should;
- You have had a heart attack (myocardial infarction) that may lead to a weakening of the heart. MYLAN-LISINOPRIL slows the weakening down.

What it does:

MYLAN-LISINOPRIL is an angiotensin converting enzyme (ACE) inhibitor. You can recognize ACE inhibitors because their medicinal ingredient ends in '-PRIL'.

This medicine does not cure your disease. It helps to control it. Therefore, it is important to continue taking MYLAN-LISINOPRIL regularly even if you feel fine.

MYLAN-LISINOPRIL works by widening your blood vessels, which helps reduce your blood pressure and makes it easier for your heart to pump blood to all parts of your body.

When it should not be used:

Do not take MYLAN-LISINOPRIL if you:

- Are allergic to lisinopril or to any non-medicinal ingredient in the formulation.
- Have experienced an allergic reaction (angioedema) with swelling of the hands, feet or ankles, face, lips, tongue, throat,

or sudden difficulty breathing or swallowing to any ACE inhibitor or without a known cause. Be sure to tell your doctor, nurse or pharmacist that this has happened to you.

- Have been diagnosed with hereditary angioedema: an increased risk of getting an allergic reaction that is passed down through families. This can be triggered by different factors, such as surgery, flu, or dental procedures.
- Are already taking a blood pressure-lowering medicine containing aliskiren (such as Rasilez) and you have diabetes or kidney disease.
- Are pregnant or intend to become pregnant. Taking MYLAN-LISINOPRIL during pregnancy can cause injury or even death to your baby.
- Are breastfeeding. MYLAN-LISINOPRIL passes into breast milk.
- Are less than 6 years old.
- Are 6 to 16 years old with severe kidney problems.

What the medicinal ingredient is:

Lisinopril

What the important nonmedicinal ingredients are:

- Mannitol 60
- Dibasic Calcium Phosphate
- Iron Oxide Red #30
- Starch
- Magnesium Stearate
- Talc

What dosage forms it comes in:

MYLAN-LISINOPRIL is supplied as 5 mg, 10 mg and 20 mg tablets for oral administration.

WARNINGS AND PRECAUTIONS

Serious Warning and Precautions – Pregnancy

MYLAN-LISINOPRIL should not be used during pregnancy. If you discover that you are pregnant while taking MYLAN-LISINOPRIL, stop the medication and contact your doctor, nurse, or pharmacist as soon as possible.

Before you use MYLAN-LISINOPRIL talk to your doctor, nurse or pharmacist if you:

IMPORTANT: PLEASE READ

- Are allergic to any drug used to lower blood pressure.
- Have recently received or are planning to get allergy shots for bee or wasp stings.
- Have narrowing of an artery or a heart valve.
- Have had a heart attack or stroke.
- Have heart failure.
- Have diabetes, liver or kidney disease.
- Are on dialysis.
- Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.
- Are taking a salt substitute that contains potassium, potassium supplements, or a potassium-sparing diuretic (a specific kind of “water pill”).
- Are on a low-salt diet.
- Are taking a medicine that contains aliskiren, such as Rasilez, used to lower high blood pressure. The combination with MYLAN-LISINOPRIL is not recommended.
- Are taking an angiotensin receptor blocker (ARB). You can recognize an ARB because its medicinal ingredient ends in “-SARTAN”.
- Are receiving gold (sodium aurothiomalate) injections.
- Are taking drugs such as:
 - o Temsirolimus and everolimus (used to treat cancer),
 - o Sirolimus (used to prevent organ rejection after a transplant).

Taking ACE inhibitors, such as MYLAN-LISINOPRIL with these types of drugs may increase your chances of having an allergic reaction (angioedema).

Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.

You may become sensitive to the sun while taking MYLAN-LISINOPRIL. Exposure to sunlight should be minimized until you know how you respond.

If you are going to have surgery and will be given an anesthetic, be sure to tell your doctor or dentist that you are taking MYLAN-LISINOPRIL.

Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to MYLAN-LISINOPRIL. Dizziness, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with MYLAN-LISINOPRIL:

- Agents increasing serum potassium, such as a salt substitute that contains potassium, potassium supplements, or a potassium-sparing diuretic (a specific kind of “water pill”).
- Allopurinol used to treat gout.
- Drugs to treat diabetes such as:
 - o Insulin,
 - o Oral medications (such as sulphonylureas).Your dose of these types of drugs may need to be changed when taking them in combination with MYLAN-LISINOPRIL.
- Temsirolimus and everolimus (drugs to treat cancer)..
- Gold for the treatment of rheumatoid arthritis.
- Lithium used to treat bipolar disease.
- Non-steroidal anti-inflammatory medicines (NSAIDs), used to reduce pain and swelling. Examples include ibuprofen, naproxen, and celecoxib.
- Blood pressure-lowering drugs, including diuretics (“water pills”), aliskiren-containing products (e.g. Rasilez), or angiotensin receptor blockers (ARBs).
- Sirolimus, a drug used to prevent the organ rejection after a transplant.

PROPER USE OF THIS MEDICATION

Take MYLAN-LISINOPRIL exactly as prescribed. It is recommended to take your dose at about the same time every day.

Swallow the tablet with a drink of water. It does not matter if you take MYLAN-LISINOPRIL before or after food.

IMPORTANT: PLEASE READ

Do not stop taking your tablets if you are feeling well, unless your doctor tells you.

Usual dose:

Adults

High blood pressure: the usual recommended starting dose is 10 mg taken once daily.

Heart failure: the usual recommended starting dose is 2.5 mg taken once a day. The usual long-term dose is 5 to 35 mg taken once daily.

Following a heart attack: the usual recommended starting dose is 5 mg on day 1 and day 2, then 10 mg taken once a day.

Children (6 years of age or older)

Children weighing 20 to less than 50 kg: the recommended starting dose is 2.5 mg. The maximum dose is 20 mg.

Children weighing 50 kg or more: the recommended starting dose is 5 mg. The maximum dose is 40 mg.

Overdose:

If you think you have taken too much MYLAN-LISINOPRIL contact your doctor, nurse, pharmacist, hospital emergency department or regional Poison control Centre immediately, even if there are no symptoms.

Missed Dose:

If you have forgotten to take your dose during the day, carry on with the next one at the usual time. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects may include:

- dizziness (or light-headedness), drowsiness, fatigue, headache, tiredness, weakness (loss of strength)
- cough, running nose
- itching, psoriasis, sinus pain, skin rash, wheezing
- abdominal pain, diarrhea, nausea, stomach pain and indigestion, vomiting
- confusion, feeling sleepy or difficulty in going to sleep, mood changes (including signs of depression), seen and/or heard hallucinations, strange dreams
- changes in the way things smell or taste, dry mouth, numbness or tingling in the fingers or toes
- rapid heartbeat
- impotence

- hair loss
- anemia

In patients with high blood pressure, fainting is uncommon. However, fainting may become common in patients with heart failure.

In patients with coronary heart disease, an excessive drop in blood pressure may be experienced.

If any of these affects you severely, tell your doctor, nurse or pharmacist.

MYLAN-LISINOPRIL can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect		Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention
		Only if severe	In all cases	
Common	Low Blood Pressure: Dizziness, fainting, lightheadedness May occur when you go from lying or sitting to standing up.	√		
	Increased levels of potassium in the blood: irregular heartbeat, muscle weakness and generally feeling unwell		√	
Uncommon	Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing			√

IMPORTANT: PLEASE READ

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect	Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention	
	Only if severe	In all cases		
	Kidney Disorder: change in frequency of urination, nausea, vomiting, swelling of extremities, fatigue		√	
	Liver and Pancreas Disorder: yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite		√	
	Electrolyte Imbalance: weakness, drowsiness, muscle pain or cramps, irregular heartbeat		√	
Rare	Decreased Platelets: bruising, bleeding, fatigue and weakness		√	
	Decreased White Blood Cells: infections, fatigue, fever, aches, pains, and flu-like symptoms		√	

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect	Talk with your doctor or pharmacist		Stop taking drug and seek immediate emergency medical attention	
	Only if severe	In all cases		
Very rare	Serious Skin Reactions (Steven-Johnson Syndrome, Toxic Epidermal Necrolysis): any combination of itchy skin, rash, redness, blistering and peeling of the skin and/or of the lips, eyes, mouth, nasal passages or genitals, accompanied by fever, chills, headache, cough, body aches or joint pain.			√

This is not a complete list of side effects. For any unexpected effects while taking MYLAN-LISINOPRIL, contact your doctor or pharmacist.

HOW TO STORE IT

Store between 15°C and 30°C. Keep out of reach and sight of children.

Keep your tablets in the container they came in.

Do not take your tablets after the expiry date on the containers.

Return any unused MYLAN-LISINOPRIL tablets to your pharmacist.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at MedEffect (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about MYLAN-LISINOPRIL:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](#); or by calling 1-800-575-1379
- This document can be found at: www.mylan.ca.

This leaflet was prepared by Mylan Pharmaceuticals ULC
Etobicoke, Ontario M8Z 2S6

Last revised: December 19, 2016



Mylan Pharmaceuticals ULC
Etobicoke, ON M8Z 2S6
1-800-575-1379
www.mylan.ca